Brazil’s Health Regulatory Agency has approved authorization for emergency use of the COVID-19 antibody treatment Regkirona developed by South Korean pharmaceutical giant Celltrion. 

The company said Thursday that it acquired the authorization after submitting results of its phase one, two and three clinical trials. It also presented results of preclinical trials regarding variants of COVID-19. 

Brazilian health authorities plan to use Regkirona on adults with mild symptoms but who are at high risk, as well as on moderate cases. 

According to Celltrion, Brazil’s daily COVID-19 cases reached around 35-thousand on Wednesday, raising the country's cumulative caseload to some 20-point-two million. The nation's death toll stands at 564-thousand-800.